{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:21:21Z","timestamp":1780564881616,"version":"3.54.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Barrett\u2019s esophagus (BE) is a metaplastic condition predisposing to esophageal adenocarcinoma. Currently, proton pump inhibitors are a mainstay of therapy for gastro-esophageal reflux disease (GERD), a known risk factor for BE, and as a chemopreventive agent in preventing neoplastic progression in BE. Recently, the U.S. Food and Drug Administration approved vonoprazan, part of a new class of acid-suppressive agents called potassium competitive acid blockers (PCABs). While there have been several randomized trials evaluating the use of vonoprazan in GERD management, there are currently limited data on the use of PCABs in BE populations. This review summarizes key existing data of PCABs in acid-related disorders associated with BE, highlights opportunities to explore the potential utility of PCABs in BE-related endpoints, and identifies challenges in the study of PCABs in BE outcomes.<\/jats:p>","DOI":"10.1093\/dote\/doag033","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:37:34Z","timestamp":1774355854000},"source":"Crossref","is-referenced-by-count":1,"title":["Potassium competitive acid blockers in Barrett\u2019s esophagus: lessons from gastro-esophageal reflux disease and future directions"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-1659","authenticated-orcid":false,"given":"Margaret J","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine , Stanford, CA \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Triadafilopoulos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, UT MD Anderson Cancer Center , Conroe, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"issue":"6","key":"2026041304191170500_ref1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2026041304191170500_ref2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker Vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2026041304191170500_ref3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut."},{"issue":"5","key":"2026041304191170500_ref4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/jgh.16475","article-title":"A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease","volume":"39","author":"Simadibrata","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"2026041304191170500_ref5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3892\/br.2017.1035","article-title":"Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors","volume":"8","author":"Mizuno","year":"2018","journal-title":"Biomed Rep"},{"issue":"10145","key":"2026041304191170500_ref6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(18)31388-6","article-title":"Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial","volume":"392","author":"Jankowski","year":"2018","journal-title":"Lancet."}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/2\/doag033\/68035298\/doag033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/2\/doag033\/68035298\/doag033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:19:17Z","timestamp":1776068357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag033\/8651849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag033","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,2]]},"article-number":"doag033"}}